Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial

By Anghelescu I.   Szegedi A.   Schlegel S.   Weigmann H.   Hiemke C.   Wetzel H.  

European Neuropsychopharmacology, Vol. 8, Iss. 4, 1998-12 ,pp. : 315-320

Elsevier

Access to resources Recommend Favorite

Problems Arising from the Generalising of Treatment Efficacy from Clinical Trials in Alzheimer's Disease: Mistaking Statistical Significance as Clinical Significance

By Becker R.  

Clinical Drug Investigation, Vol. 19, Iss. 1, 2000-01 ,pp. : 33-41

Adis International

Access to resources Recommend Favorite

Evaluation of memantine for the treatment of Alzheimer’s disease

By Ferris Steven H  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 12, 2003-12 ,pp. : 2305-2313

Informa Healthcare

Access to resources Recommend Favorite

Safety and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% in the Treatment of Bacterial Conjunctivitis: Data from Six Clinical and Phase I Safety Studies

By Comstock Timothy L.  

Clinical Drug Investigation, Vol. 30, Iss. 10, 2010-10 ,pp. : 675-685

Adis International

Access to resources Recommend Favorite

Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan

By Nakamura Yu   Kitamura Shin   Homma Akira   Shiosakai Kazuhito   Matsui Daiju  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 7, 2014-05 ,pp. : 913-925

Informa Healthcare

Access to resources Recommend Favorite